<?xml version="1.0" encoding="UTF-8"?>
<p id="Par11">Consent was obtained from 111 high risk neuroblastoma subjects in Stratum 1 and 39 subjects in Stratum 2 at 21 clinical sites across the US; 101 in Stratum 1 and 39 in Stratum 2 were determined eligible for enrollment. Of the ten Stratum 1 screen failures, four had demonstrable progression of NB, five did not complete screening procedures within the mandated 120-day window following completion of antibody/
 <italic>cis</italic>-retinoic acid therapy, and one had a systemic fungal infection. Response to induction therapy was not an eligibility criterion.
</p>
